Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical, biotechnology, medical device, and healthcare companies. In the following sections, we analyze data and trends in securities class actions across all industries and in the life sciences industry in…
Michael Siekman, Huiya Wu, Allegra Padula, and Riley Wyberg will present their data-driven analyses of trends in BPCIA litigation and relevant takeaways. With 10 years of litigation since the first BPCIA complaint on NEUPOGEN (filgrastim) was filed in 2014, trends are becoming apparent that should cause all biopharma companies to…
Arman Oruc, Andy Lacy, Sarah Jordan, and Stephen Mavroghenis are excited to invite you to join Goodwin for an in-person, engaging discussion on antitrust in life sciences transactions, navigating global merger control investigations and what to do when your deal hits a regulatory brick wall. We’ll cover the latest trends in early-stage deals,…
